108290-86-4

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 2-AMINO-1H-PYRROLE-3-CARBOXYLATE is used as a reagent for the synthesis of pyrrolo pyrimidines, which are important in the development of glucocerebrosidase activators. These activators play a significant role in the treatment of medical disorders, particularly those related to the malfunctioning of glucocerebrosidase enzyme. By enhancing the activity of this enzyme, pyrrolo pyrimidines can help alleviate the symptoms and complications associated with these disorders, making ETHYL 2-AMINO-1H-PYRROLE-3-CARBOXYLATE a valuable component in the pharmaceutical industry.

Upstream product

• 107-20-0 2-chloroethanal 
• 50551-10-5 ethyl amidinoacetate 
• 57508-48-2 carbethoxyacetamidine hydrochloride 
• 97-97-2 chloroacetaldehyde dimethyl acetal 
• 4360-63-8 2-bromomethyl-1,3-dioxolane 
• 621-62-5 chloroacetaldehyde diethyl acetal 

Downstream Products

• 108290-88-6 Ethyl 2-Amino-1-benzyloxymethylpyrrole-3-carboxylate 
• 187724-73-8 2-(5-amino-4-ethoxycarbonyl-1H-pyrrol-2-yl)-N-benzyl-pyridinium bromide 
• 5655-01-6 3H,4H,5H-pyrrolo[3,2-d]pyrimidin-4-one 

Relevant academic research and scientific papers

Synthesis and transformations of pyrrolo[1,2-a][1,3,5]-triazines

Pyrrolotriazines and related fused azaheterocycles have high potential for the synthesis of bioactive compounds, especially as a purine base isoster in carbon linked nucleosides. Although many structurally related compounds have already been synthesized and used in medicinal chemistry, pyrrolo[1,3,5]triazines have barely been described. The present work describes the synthesis of such heterocycles via condensation of 2-amino-3-ethoxycarbonylpyrrole with ethoxycarbonyliso(thio)cyanate. In a brief reactivity study of the obtained fused pyrroles, O- and S-alkylation, ester hydrolysis as well as regioselective bromination at the 6-position was demonstrated.

Synthesis method of 4-chloropyrrolopyrimidine

The invention belongs to the technical field of chemical synthesis, and discloses a synthesis method of 4-chloropyrrolopyrimidine, which comprises the following steps: adding an acid solution into anorganic mixed solution of a compound of a formula III, a

Continuous preparation method for 2-aminopyrrolyl-3-ethyl carboxylate

The invention provides a continuous preparation method for 2-aminopyrrolyl-3-ethyl carboxylate. The preparation method comprises the steps: continuously feeding a trichloroacetaldehyde solution to a first continuous reactor to carry out continuous acid catalyzed depolymerization on trichloroacetaldehyde, so as to a chloroacetaldehyde solution; and continuously feeding a 3-amino-3-imidoethyl propionate solution, an alkali solution and the chloroacetaldehyde solution to a second continuous reactor for a condensation reaction, thereby obtaining the 2-aminopyrrolyl-3-ethyl carboxylate. According to the continuous process, the restriction to anhydrous chloroacetaldehyde is broken through, the anhydrous chloroacetaldehyde is prepared by a continuous reaction, the reaction speed is higher than that of batches, and the yield is higher; and when the prepared chloroacetaldehyde solution is directly applied to the condensation reaction of next step, the material proportioning ratio is more controllable, the front and rear two steps can be compatible, and thus, the yield of the 2-aminopyrrolyl-3-ethyl carboxylate is globally increased. In addition, due to the continuous process, a scaling effect of the batches is avoided, and high yield during industrial application is also guaranteed.

SUBSTITUTED 4-METHYL-PYRROLO[1.2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY

Disclosed are new small molecules having a 4-methylpyrrrolo[l,2-a]pyrimidine- 8-carboxamide core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules which may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease. The small molecules may contain a fluorophore or may be conjugated to a fluorophore in order to prepare a fluorescent probe for use in high throughput screening methods to identify new modulators of glucocerebrosidase activity via fluorescence polarization.

SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted pyrrolo[l,2-a]pyrimi dines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidines compounds described herein include substituted 2,4-dimethyl-N-phenylpyrrolo[l,2-a]pyrimidine-8-carboxamide compounds and variants thereof.

Substituted pyrazolo[1,5-A] pyrimidines as calcium receptor modulating agents

There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7-membered ring; ring B is an optionally substituted 5- to 7-membered heterocyclic ring; X1 is CR1/